Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
22 Dicembre 2023 - 10:30PM
Cellectis Reports Results from Shareholders Meeting Held on
December 22, 2023
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a
clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, held today a shareholders general meeting at 2:30 p.m.
CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris,
France.
At the meeting, resolutions 1 through 5 as well
as resolutions 7 and 8 were adopted and resolution 6 was rejected,
consistent with the recommendations of the board of directors.
Cellectis’ shareholders supported the
contemplated $140M additional investment by AstraZeneca in the
Company, to be effected by way of subscription of 10,000,000 newly
created “class A” convertible preferred shares and 18,000,000 newly
created “class B” convertible preferred shares, in each case at a
price of $5.00 per share (the “Additional Investment”).
The completion of the Additional Investment
remains subject to the clearance of such investment from the French
Ministry of Economy pursuant to applicable foreign direct
investment regulations, and other customary closing conditions.
The Company’s shareholders also approved the
appointments of Mr. Marc Dunoyer and Dr. Tyrell Rivers as directors
of the Cellectis board of directors, which appointment remains
subject to the completion of the Additional Investment.
“We are grateful to our shareholders for
supporting the Additional Investment and we are looking forward to
welcoming Mr. Dunoyer and Dr. Rivers to our board of directors.
Their extensive experience in the pharma industry will be an
additional asset for the Company. This Additional Investment would
provide meaningful and valued perspectives to our common ambition
of bringing potentially life-saving therapies to patients with
unmet medical needs” said Jean Pierre Garnier, Chairman of the
Board of Directors at Cellectis.
Mr. Marc Dunoyer is Chief Strategy Officer of
AstraZeneca and Chief Executive Officer of Alexion, AstraZeneca
Rare Disease. He had previously served as an Executive Director and
AstraZeneca’s Chief Financial Officer from November 2013. Mr. Marc
Dunoyer’s career in pharmaceuticals, which has included periods
with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him
extensive industry experience. He is a qualified accountant and
joined AstraZeneca in 2013, serving as Executive Vice-President,
Global Product and Portfolio Strategy from June to October 2013.
Prior to that, he served as Global Head of Rare Diseases at GSK and
(concurrently) Chairman, GSK Japan. Mr. Dunoyer is a member of the
Boards of Orchard Therapeutics Plc and JCR Pharmaceuticals. He
holds an MBA from HEC Paris and a Bachelor of Law degree from Paris
University.
Dr. Tyrell Rivers is Executive Director of
Corporate Ventures at AstraZeneca, where he is responsible for
creating and executing innovative, value-enhancing business
strategies. Prior to assuming this role in 2014, he worked at
MedImmune Ventures, specializing in life science investing. Earlier
in his career, Dr. Rivers held various positions at Merck &
Co., where he led technical support for commercial vaccines and
directed global business initiatives for accessing key technologies
for research and development. He currently serves as a Board member
of ADC Therapeutics, Cerapedics, and Quell Therapeutics. Dr. Rivers
holds his B.S. in Chemical Engineering from the Massachusetts
Institute of Technology, a Ph.D. in Chemical Engineering from the
University of Texas at Austin, and an M.B.A. from the New York
University Stern School of Business.
The detailed results of the vote and the
resolutions are available on Cellectis’
website:https://www.cellectis.com/en/investors/general-meetings/
About CellectisCellectis is a
clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hemopoietic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 23 years of experience and
expertise in gene editing, Cellectis is developing life-changing
product candidates utilizing TALEN®, its gene editing technology,
and PulseAgile, its pioneering electroporation system to harness
the power of the immune system in order to treat diseases with
unmet medical needs. Cellectis’ headquarters are in Paris, France,
with locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS).
Cautionary Statement This press
release contains certain “forward-looking” statements within the
meaning of applicable securities laws, including the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as “contemplated”,
“subject to”, “looking forward”, “would”, and similar expressions.
These forward-looking statements are made in light of information
currently available to us and based on assumptions that Cellectis
considers to be reasonable. However, they are subject to numerous
risks and uncertainties, including the risk that conditions to
closing, including necessary regulatory approvals, are not
satisfied. Furthermore, many other important risks factors and
uncertainties, including those described in our Annual Report on
Form 20-F filed with the U.S. Securities and Exchange Commission
(the SEC) on March 14, 2023 (as amended on October 31, 2023), under
“Risk Factors” (copies of which are available on
www.cellectis.com), may adversely affect such forward-looking
statements and cause our actual results, performance or
achievements to be materially different from those expressed or
implied by the forward-looking statements. Except as required by
law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results
could differ materially from those anticipated in the
forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contact: Patricia Sosa
Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,
media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson, LifeSci Advisors,
+1 617 430 7577
- Cellectis GM December 22 2023_PR voting results.pdf
Grafico Azioni Cellectis Nom Eo 05 (TG:ZVA)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Cellectis Nom Eo 05 (TG:ZVA)
Storico
Da Ott 2023 a Ott 2024